UEV1A Antibody

What is UEV1A/UBE2V1 and how does it function biochemically?

UEV1A (Ubiquitin-conjugating Enzyme Variant 1a), also known as UBE2V1, belongs to the Ubiquitin-conjugating (E2) enzyme family. Human UEV1A has a predicted molecular weight of 19 kDa, while its mouse ortholog weighs approximately 16.5 kDa, with the two sharing 89% amino acid sequence identity. Unlike typical E2 enzymes, UEV1A lacks an active site cysteine residue in its catalytic core domain, rendering it enzymatically inactive independently .

How do UEV1A splicing variants differ functionally?

UEV1 splicing variants, particularly UEV1A and UEV1C, exhibit distinct functional properties despite their structural similarities:

UEV1A contains a unique non-conserved 30 amino acid N-terminal tail that is absent in UEV1C. This structural difference creates significant functional divergence . Experimental evidence demonstrates that only UEV1A, not UEV1C, activates the NF-κB signaling pathway through promoting IκBα phosphorylation and NF-κB nuclear translocation .

In cancer models, overexpression of UEV1A alone enhances cell migration, invasion, and metastasis both in vitro and in vivo, while UEV1C overexpression fails to produce these effects . This functional specificity extends to xenograft models, where UEV1A overexpression promotes tumor growth and metastasis, but UEV1C does not affect tumor formation .

Studies show that truncated UEV1A missing its N-terminal region behaves similarly to MMS2 regarding subcellular localization and K63-linked ubiquitin chain formation patterns, suggesting UEV1C may have functions more closely related to MMS2 than UEV1A .

How does UEV1A differ from MMS2?

UEV1A and MMS2, though both acting as UBE2N/Ubc13 binding partners, demonstrate significant functional differences:

The primary structural distinction is UEV1A's non-conserved 30 amino acid N-terminal tail, absent in MMS2. This structural difference translates to functional divergence - UEV1A can activate NF-κB signaling, while MMS2 cannot . Experimental evidence confirms that when the N-terminal region of UEV1A is removed, the truncated protein behaves like MMS2 regarding subcellular localization and promotion of K63-linked ubiquitin chains in vitro .

Functional studies reveal that overexpression of UEV1A, but not MMS2, promotes cell migration, invasion, and tumor metastasis in breast cancer models . This indicates fundamentally different roles in cellular processes despite their structural similarities in the core domain that interacts with Ubc13.

The subcellular distribution patterns also differ between these proteins, affecting their participation in specific cellular pathways and their ability to interact with unique sets of signaling components .

Which cell lines are most suitable for UEV1A functional studies?

Several established cell lines serve as valuable models for UEV1A research, each offering specific advantages:

Breast cancer cell lines MCF7 and MDA-MB-231 are frequently employed in UEV1A studies, particularly for investigating breast cancer progression and metastasis . These lines exhibit different levels of UEV1A expression and varying metastatic potential, making them ideal for correlation studies between UEV1A levels and invasive behaviors. MDA-MB-231 cells show a 2.7-fold increase in UEV1A expression compared to normal breast cells, providing a suitable model for studying moderate UEV1A overexpression effects .

The human colon carcinoma cell line HCT116 has also proven useful in UEV1A-related research . For establishing baseline expression levels, normal breast cells such as MCF-10A are commonly included as comparative controls .

When selecting cell lines, researchers should consider the baseline UEV1A expression, metastatic potential, and specific signaling pathway activities relevant to their research questions. Cell line authentication and regular testing for mycoplasma contamination remain essential for reliable results.

What are the optimal methods for manipulating UEV1A expression?

Researchers can manipulate UEV1A expression through several complementary approaches:

For overexpression studies:

• Cloning UEV1A open reading frames into expression vectors such as pcDNA4.0/TO/HA(+) enables both transient and stable transfection approaches .

• Inducible expression systems, particularly Tet-on promoters, provide controlled, dose-dependent UEV1A expression, allowing precise temporal regulation .

• Stable UEV1A-overexpressing cell lines can be established through selection with appropriate antibiotics for long-term studies .

For downregulation experiments:

• shRNA delivered via lentiviral particles effectively reduces endogenous UEV1A expression with sustained effects .

• siRNA transfection offers transient knockdown options for short-term studies .

• Multiple independent shRNA constructs (e.g., shUEV1-1 and shUEV1-2) should be employed to validate findings and minimize off-target effects .

Structure-function studies benefit from creating specific UEV1A mutants, such as the F38E mutation that abolishes Ubc13 interaction, allowing researchers to distinguish between UEV1A's scaffold function and its role in promoting ubiquitination .

The selection of manipulation strategy should align with experimental timeline requirements, desired expression levels, and specific research questions regarding UEV1A function.

How can researchers quantitatively assess UEV1A expression levels?

Accurate quantification of UEV1A expression requires combining multiple complementary techniques:

Quantitative Real-Time PCR (qRT-PCR) provides sensitive measurement of UEV1A mRNA transcript levels. This approach can detect relative expression changes as small as 40-60% reduction following shRNA treatment, making it suitable for monitoring knockdown efficiency .

Western blotting using UEV1A-specific antibodies quantifies protein levels. For tagged versions (e.g., HA-tagged UEV1A), antibodies against the tag offer high specificity. Densitometric analysis of band intensity provides semi-quantitative measurement .

Microarray analysis enables examination of UEV1A expression alongside thousands of other genes, particularly valuable when assessing global transcriptional changes following UEV1A manipulation. Inducible systems combined with microarray analysis reveal direct UEV1A-dependent gene expression patterns .

TissueScan microarray techniques allow measurement of UEV1A expression across diverse tissue samples, including normal and cancerous tissues. This approach has revealed up to 20-fold increases in UEV1A levels in some breast cancer samples compared to normal tissue .

For comprehensive assessment, researchers should combine transcript-level measurements with protein quantification to account for potential post-transcriptional regulation of UEV1A.

How does UEV1A activate the NF-κB signaling pathway?

UEV1A activates NF-κB signaling through a well-defined molecular cascade:

Initially, UEV1A forms a heterodimer with Ubc13, creating an active E2 ubiquitin-conjugating complex . This complex, in concert with specific RING-finger E3 ligases such as TRAF2 and TRAF6, catalyzes the formation of K63-linked polyubiquitin chains on target proteins in the NF-κB pathway . These K63-linked chains serve as binding platforms for proteins including NEMO and TAB2/3, which are essential components of the IκB kinase (IKK) complex .

Upon recruitment, the activated IKK complex phosphorylates IκBα, triggering its degradation and subsequent release of sequestered NF-κB transcription factors . These freed NF-κB molecules translocate to the nucleus where they activate transcription of target genes involved in inflammation, cell survival, and metastasis .

Multiple experimental approaches confirm this mechanism: overexpression of UEV1A, but not UEV1C or MMS2, promotes IκBα phosphorylation and NF-κB nuclear translocation . Importantly, UEV1A mutants that cannot interact with Ubc13 (F38E mutant) fail to activate NF-κB, confirming the requirement for Ubc13-UEV1A interaction in this signaling pathway .

What downstream targets does UEV1A regulate in cancer progression?

UEV1A regulates several critical downstream targets that collectively promote cancer progression:

Matrix Metalloproteinase-1 (MMP1) represents one of the most thoroughly characterized UEV1A targets. UEV1A-mediated NF-κB activation significantly upregulates MMP1 expression, which plays a crucial role in cancer cell invasion and metastasis by degrading extracellular matrix components . Experimental evidence confirms that MMP1 overexpression can override the anti-metastatic effects of UEV1A depletion, establishing it as a key mediator of UEV1A-driven metastasis .

CT45A has recently been identified as another UEV1A-regulated gene in breast cancer cells. When UEV1A is overexpressed, CT45A levels increase significantly; conversely, UEV1A depletion reduces CT45A expression . This regulation appears to contribute to breast cancer cell migration and potentially metastasis.

Beyond these specific targets, UEV1A indirectly regulates numerous NF-κB target genes involved in cell survival, proliferation, inflammation, and metastasis . Comprehensive microarray analyses of cells with inducible UEV1A expression have identified additional genes with altered expression patterns following UEV1A overexpression, further expanding the network of UEV1A-regulated genes involved in cancer progression .

How does UEV1A promote breast cancer metastasis?

UEV1A orchestrates breast cancer metastasis through a multi-faceted mechanism:

The primary pathway involves NF-κB activation through UEV1A-Ubc13 complex formation, which promotes K63-linked polyubiquitination of pathway components. This leads to IκBα phosphorylation and degradation, allowing NF-κB nuclear translocation and subsequent transcriptional activation .

Among NF-κB target genes, MMP1 upregulation proves particularly critical. Elevated MMP1 expression facilitates cancer cell invasion through tissue barriers by degrading extracellular matrix components, directly promoting metastasis . Experimental evidence confirms that MMP1 reconstitution can rescue the metastatic phenotype in UEV1A-depleted cells, establishing it as a key mediator .

UEV1A overexpression significantly enhances breast cancer cell migration and invasion capabilities, as demonstrated in multiple in vitro assays . These cellular behaviors translate to increased tumor growth and metastasis in vivo, as confirmed in xenograft studies .

Recent research suggests UEV1A also upregulates CT45A expression, potentially contributing to breast cancer cell migration and metastasis through complementary mechanisms .

Notably, even moderate UEV1A overexpression (2.7-fold in MDA-MB-231 cells) significantly impacts metastatic potential, while partial depletion dramatically reduces metastasis in experimental models, highlighting its central role in this process .

How does the N-terminal region determine UEV1A's specific functions?

The N-terminal region of UEV1A, comprising the first 30 amino acids, serves as the critical molecular determinant differentiating its functions from other UEV family members:

This domain enables UEV1A to specifically activate the NF-κB signaling pathway, a function absent in UEV1C and MMS2 which lack this region . The N-terminal domain influences UEV1A's subcellular distribution, affecting its interaction capacity with specific signaling components. Experimental evidence shows that when this region is truncated, UEV1A behaves similarly to MMS2 regarding cellular localization .

The N-terminal region appears to modulate how UEV1A, in complex with Ubc13, promotes K63-linked polyubiquitin chain formation versus di-ubiquitin chains, creating significant implications for downstream signaling events . This domain likely mediates interactions with specific proteins involved in signaling pathways beyond the core Ubc13 interaction shared with other UEV family members .

Most importantly, experimental evidence confirms this region is essential for UEV1A's tumor growth and metastasis-promoting functions, as these activities are not observed with UEV1C or MMS2 . Based on these findings, researchers have concluded that "a desired inhibitor should target the N-terminal region of Uev1A instead of the Ubc13-Uev1 interface" , highlighting this domain's therapeutic significance.

What approaches can differentiate UEV1A-dependent from UEV1A-independent metastasis mechanisms?

Distinguishing UEV1A-dependent from UEV1A-independent mechanisms requires sophisticated experimental strategies:

Comparative genetic manipulation provides initial differentiation - researchers should compare effects of UEV1A manipulation with related proteins (UEV1C, MMS2) to identify UEV1A-specific outcomes . Using UEV1A mutants that disrupt specific interactions (e.g., F38E mutant disrupting Ubc13 binding) helps determine which metastatic processes depend on particular UEV1A functions .

Rescue experiments offer powerful mechanistic insights. In UEV1A-depleted cells, reintroducing wild-type UEV1A or specific downstream targets (e.g., MMP1) can identify essential mediators of UEV1A-driven metastasis . Studies show MMP1 reconstitution can restore metastatic potential in UEV1A-depleted cells, establishing it as a critical UEV1A-dependent factor .

Pathway-specific inhibition helps distinguish primary mechanisms. Using NF-κB pathway inhibitors determines whether UEV1A promotes metastasis primarily through this pathway or involves additional mechanisms .

Temporal control via inducible expression systems (Tet-on) allows observation of sequential metastatic events, distinguishing early UEV1A-dependent processes from later UEV1A-independent mechanisms .

Comprehensive gene expression analysis through microarray or RNA-seq identifies genes differentially expressed with UEV1A manipulation, enabling comparison with known metastasis signatures to identify unique UEV1A-regulated patterns .

What therapeutic strategies targeting UEV1A show promise for cancer treatment?

Several therapeutic approaches targeting UEV1A demonstrate potential for cancer treatment:

More selective approaches targeting UEV1A's N-terminal region could provide greater specificity. Since this domain determines UEV1A's unique functions, inhibitors selectively targeting this region may effectively block pathological activities while preserving normal ubiquitination processes mediated by related complexes .

RNA interference approaches show significant promise in preclinical models. UEV1A depletion using shRNA dramatically reduced tumor growth and metastasis in xenograft models, suggesting siRNA or shRNA delivery systems targeting UEV1A could be developed as therapeutic strategies .

Targeting downstream effectors provides an alternative approach. Since MMP1 functions as a critical mediator of UEV1A-driven metastasis, MMP1 inhibitors could potentially counteract effects of UEV1A overexpression in cancer cells .

These therapeutic strategies gain relevance from clinical observations that UEV1A is significantly overexpressed in breast cancer samples (up to 20-fold compared to normal tissue) , making it a clinically relevant target for intervention.

How can UEV1A expression patterns inform cancer prognosis and treatment decisions?

UEV1A expression patterns offer valuable prognostic and predictive information for cancer management:

Clinical correlation studies have found significant variation in UEV1A expression among breast cancer samples, with increases of up to 20-fold compared to normal tissue . This contrasts with the relatively stable expression (less than 2-fold variation) observed in normal breast samples, suggesting UEV1A upregulation is a cancer-specific phenomenon .

The correlation between UEV1A expression and tumorigenic indicators supports its potential as a prognostic marker . Experimental evidence demonstrates that even moderate UEV1A overexpression (2.7-fold) significantly enhances metastatic potential, while its depletion dramatically reduces metastasis , suggesting UEV1A levels may predict metastatic risk.

UEV1A expression could potentially guide treatment selection, as researchers have observed that "a certain percentage of breast cancer samples with NF-κB activation is due to elevated UEV1A expression" . Patients with UEV1A-driven NF-κB activation might particularly benefit from therapies targeting this pathway.

For clinical implementation, standardized quantification of UEV1A expression through immunohistochemistry or RT-PCR in tumor samples would need validation in large patient cohorts with long-term follow-up to establish reliable cutoff values for risk stratification and treatment decisions.

What in vivo models best reflect UEV1A-mediated cancer progression?

Several in vivo models effectively capture UEV1A-mediated cancer progression:

Xenograft mouse models using human breast cancer cells with manipulated UEV1A expression provide the most direct evidence of UEV1A's impact on tumor formation and metastasis . These models demonstrate that UEV1A overexpression enhances tumor growth and metastatic spread, while its depletion reduces or completely abolishes these effects .

Lung metastasis models, where cancer cells are injected into the tail vein of mice, specifically assess late stages of the metastatic cascade. This approach has revealed that even moderate depletion of UEV1A can completely abolish lung metastasis formation , highlighting UEV1A's critical role in distant colonization.

Inducible expression systems (Tet-on) in xenograft models provide temporal control over UEV1A expression, allowing researchers to distinguish between its roles in tumor initiation versus progression . This approach confirmed that the enhanced tumorigenesis and metastasis were directly attributable to UEV1A overexpression, as these phenotypes were only observed under doxycycline-induced conditions .

For comprehensive understanding, researchers should combine orthotopic models (tumor cells implanted into appropriate tissue) with systemic models (tail vein injection) to assess UEV1A's role across the entire metastatic cascade. Importantly, these models should incorporate immunocompetent systems when possible to account for immune interactions with UEV1A-mediated signaling.

How might UEV1A research inform treatment approaches for other ubiquitination-related diseases?

UEV1A research has broader implications beyond cancer, potentially informing treatment approaches for other ubiquitination-related diseases:

The mechanistic insights into how UEV1A modulates K63-linked polyubiquitination could inform therapeutic strategies for inflammatory disorders where NF-κB signaling plays a pathological role . Since UEV1A specifically regulates K63-linked ubiquitination without affecting K48-linked chains that target proteins for degradation, targeting UEV1A might modulate signaling pathways without disrupting protein turnover .

The structural understanding of how UEV1A's N-terminal region confers functional specificity provides a template for developing selective inhibitors targeting other ubiquitin-conjugating enzyme variants involved in diverse pathologies . This domain-specific targeting approach could minimize off-target effects while achieving pathway-specific modulation.

Experimental approaches that successfully manipulated UEV1A levels in vivo without apparent toxicity suggest that targeting components of the ubiquitination machinery can be achieved with acceptable safety profiles . This encourages exploration of similar approaches for other ubiquitination-related diseases.

The observation that even partial inhibition of UEV1A significantly impacts pathological processes while presumably preserving essential functions suggests that complete inhibition may not be necessary for therapeutic benefit . This principle of partial inhibition could guide dosing strategies for other ubiquitination-targeting therapeutics to balance efficacy with safety.